Application of programmed cell death 1/programmed cell death 1 ligand 1 inhibitor combined with anlotinib in the maintenance treatment of extensive stage small cell lung cancer
Objective To investigate the efficacy and safety of programmed cell death 1(PD-1)/programmed cell death 1 ligand 1(PD-L1)inhibitors combined with anlotinib in the maintenance treatment of extensive stage small cell lung cancer(ES-SCLC).Method A total of 80 patients with ES-SCLC were randomly divided into combination group(40 cases)and control group(40 cases)by envelope method.The control group was treated with PD-1/PD-L1 inhibitor combined with etoposide+platinum(EP)regimen after the first-line treatment,and the combined group was treated with anlotinib hydrochloride capsule on the basis of the control group.Objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS)and adverse reactions were compared between the two groups.Result The ORR and DCR in combination group were higher than those in control group,and the median PFS and median OS were longer than those in control group,the differences were statistically significant(P<0.05).The ad-verse reactions of the two groups were mainly grade 1 to grade 2,and there were no statistical significances in the inci-dence of adverse reactions between the two groups(P>0.05).Conclusion PD-1/PD-L1 inhibitor combined with anlo-tinib is effective in maintenance treatment of patients with ES-SCLC,and can effectively prolong patients'PFS and OS without increasing adverse reactions.
programmed cell death 1/programmed cell death 1 ligand 1anlotinibextensive stage small cell lung cancermaintenance treatment
NETL
NSTL
万方数据
